Table 1.
Demographic, baseline parameters and treatment duration.
| Characteristics | Mean |
|---|---|
| Age, in years (SD) | 63.6 (± 9.2) |
| Gender, n (%) | |
| Male | 77 (54.6%) |
| Female | 64 (45.4%) |
| Tumor Site, n (%) | |
| Head | 73 (51.8%) |
| Body | 22 (15.6%) |
| Tail | 2 (1.4%) |
| Multiple | 44 (31.2%) |
| Tumor Stage, n (%) | |
| I | 0 (0%) |
| II | 0 (0%) |
| III | 141 (100%) |
| IV | 0 (0%) |
| ECOG score, n (%) | |
| 0 | 72 (51.1%) |
| 1 | 58 (41.1%) |
| 2 | 11 (7.8%) |
| 3 | 0 (0%) |
| Prior chemotherapy | |
| None | 126 (85.8%) |
| Gemcitabine | 8 (5.0%) |
| Gemcitabine + Erlotinib | 5 (3.6%) |
| Gemcitabine + Cisplatin | 1 (0.7%) |
| Capecitabine | 1 (0.7%) |
| FOLFIRINOX | 3 (2.1%) |
| Unknown | 3 (2.1%) |
| Height, in cm | 170 (± 9.1) |
| Weight, in kg (SD; range) | 70.1 (± 12.3; 44–115)) |
| CA 19.9, in kU/L (SD; range; median) | 1,286.5 (± 3,272; 0.1–27,031; 230.3) |
| Timeline, in days (SD) | |
| Planning CT to treatment initiation | 9.0 (± 6) |
| Treatment duration | 38.3 (± 4) |
| Treatment completion to follow-up CT | 29.4 (± 9) |
| Planning CT to follow-up CT | 78.3 (± 11) |
CA: carbohydrate antigen, CT: computer tomogram, ECOG: Eastern Cooperative Oncology Group, FOLFIRINOX: folinic acid, fluorouracil, irinotecan and oxaliplatin.